Cargando…

Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases

The disease course of chronic lymphocytic leukemia (CLL) is frequently characterized by the occurrence of various complications, such as second primary cancer, which can impact patients’ prognoses. While therapies for CLL have evolved tremendously in the past decades, overlooking the possibility of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angotzi, Francesco, Visentin, Andrea, Scarmozzino, Federico, Cellini, Alessandro, Bertorelle, Roberta, Pizzi, Marco, Binotto, Gianni, Dei Tos, Angelo Paolo, Trentin, Livio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947735/ https://www.ncbi.nlm.nih.gov/pubmed/35323322 http://dx.doi.org/10.3390/curroncol29030122

Ejemplares similares

Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells
por: Cellini, Alessandro, et al.
Publicado: (2023)

A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency
por: Visentin, Andrea, et al.
Publicado: (2022)

Comment on: “Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients”
por: Visentin, Andrea, et al.
Publicado: (2021)

Protein Phosphorylation and Redox Status: An as Yet Elusive Dyad in Chronic Lymphocytic Leukemia
por: Pagano, Mario Angelo, et al.
Publicado: (2022)

Chronic Lymphocytic Leukemia and Myelofibrosis
por: Darawshy, Fares, et al.
Publicado: (2018)

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases
por: Visentin, Andrea, et al.
Publicado: (2017)

Mutational Profile in 75 Patients With Anti–Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets
por: Castellani, Francesca, et al.
Publicado: (2023)

P054: The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma
por: Visentin, Andrea, et al.
Publicado: (2022)

P1075: ADVANCED-STAGE CHL INTERNATIONAL PROGNOSTICATION INDEX: EXTERNAL VALIDATION IN A SINGLE-CENTER RETROSPECTIVE PATIENT DATASET AND COMPARISON TO THE HASENCLEVER IPS
por: Cellini, Alessandro, et al.
Publicado: (2023)

Refractory celiac disease and its mimickers: a review on pathogenesis, clinical-pathological features and therapeutic challenges
por: Scarmozzino, Federico, et al.
Publicado: (2023)

P005: Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study.
por: Visentin, Andrea, et al.
Publicado: (2022)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
por: Visentin, Andrea, et al.
Publicado: (2022)

From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance
por: Visentin, Andrea, et al.
Publicado: (2022)

The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy
por: Castellani, Francesca, et al.
Publicado: (2020)

Glycerophosphoinositol Promotes Apoptosis of Chronic Lymphocytic Leukemia Cells by Enhancing Bax Expression and Activation
por: Boncompagni, Gioia, et al.
Publicado: (2022)

Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma
por: Manni, Sabrina, et al.
Publicado: (2021)

PB2261: LINEZOLID AS A SAFE ANTIMICROBIAL AGENT IN THROMBOCYTOPENIC PATIENTS UNDERGOING CHEMOTHERAPY FOR HEMATOLOGIC MALIGNANCIES
por: Angotzi, F., et al.
Publicado: (2022)

Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model
por: Severin, Filippo, et al.
Publicado: (2022)

Targeted activation of the SHP-1/PP2A signaling axis elicits apoptosis of chronic lymphocytic leukemia cells
por: Tibaldi, Elena, et al.
Publicado: (2017)

p66Shc Deficiency in Chronic Lymphocytic Leukemia Promotes Chemokine Receptor Expression Through the ROS-Dependent Inhibition of NF-κB
por: Tatangelo, Vanessa, et al.
Publicado: (2022)

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
por: Fresa, Alberto, et al.
Publicado: (2022)

Bosutinib for Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2015)

P1076: A RETROSPECTIVE ANALYSIS ON OLD AND EMERGING PROGNOSTIC FACTORS IN CLASSICAL HODGKIN’S LYMPHOMA IN THE PET-GUIDED ERA
por: Cellini, A., et al.
Publicado: (2022)

Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia
por: Visentin, Andrea, et al.
Publicado: (2020)

Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia
por: Frustaci, Anna Maria, et al.
Publicado: (2022)

High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients
por: Marino, Dario, et al.
Publicado: (2022)

A bone-based 3D scaffold as an in-vitro model of microenvironment–DLBCL lymphoma cell interaction
por: Ceccato, Jessica, et al.
Publicado: (2022)

Is it primary myelofibrosis or chronic megakaryocytic leukemia?
por: Lichtman, Marshall A.
Publicado: (2022)

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
por: Angotzi, Francesco, et al.
Publicado: (2023)

Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient
por: Beaud, Jenny, et al.
Publicado: (2018)

The role of the pathologist in the decision-making process
por: Dei Tos, Angelo Paolo
Publicado: (2013)

When does a new sarcoma exist?
por: Casali, Paolo G., et al.
Publicado: (2020)

P1601: PREDICTING THE RESPONSE TO SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA (ITP): A MULTI-CENTRIC PILOT STUDY
por: Zoletto, Simone, et al.
Publicado: (2023)

Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis
por: Sousos, Nikolaos, et al.
Publicado: (2020)

In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment
por: Severin, Filippo, et al.
Publicado: (2019)

Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature
por: Maggioni, Giuseppe, et al.
Publicado: (2023)

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
por: Mauro, Francesca Romana, et al.
Publicado: (2021)

Plasma small‐extracellular vesicles enriched in miR‐122‐5p promote disease aggressiveness in pediatric anaplastic large‐cell lymphoma
por: Damanti, Carlotta Caterina, et al.
Publicado: (2023)

Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia
por: Frezzato, Federica, et al.
Publicado: (2021)

P1509: CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND PREVIOUS INFECTIONS HAD IMPACT ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH VENETOCLAX: A MULTICENTRE SEIFEM STUDY
por: Autore, Francesco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_44t94av0su8ai3m501hnbans0k